GCIA
BLACR

Gabelli & Co Investment Advisers’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio BLACR Stock Details BLACR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,800
Closed -$2.7K – 280
2024
Q4 		$2.7K Hold
20,800
– – ﹤0.01% 238
2024
Q3 		$2.27K Hold
20,800
– – ﹤0.01% 204
2024
Q2 		$2.08K Hold
20,800
– – ﹤0.01% 245
2024
Q1 		$3.12K Hold
20,800
– – ﹤0.01% 230
2023
Q4 		$3.12K Hold
20,800
– – ﹤0.01% 224
2023
Q3 		$4.78K Hold
20,800
– – ﹤0.01% 223
2023
Q2 		$3.98K Buy
+20,800
New +$3.62K ﹤0.01% 226

Gabelli & Co Investment Advisers's BLACR Position: Q1 2025 in Review

Gabelli & Co Investment Advisers sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 20,800 shares — an estimated $2.7K sold.

Gabelli & Co Investment Advisers first reported a position in BLACR in Q2 2023 and held it in 7 quarters. The position peaked at $4.78K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

  • Gabelli & Co Investment Advisers reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 20,800 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $2.7K.
  • Gabelli & Co Investment Advisers first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q2 2023 and held it in 7 quarters.
  • Gabelli & Co Investment Advisers's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $4.78K in Q3 2023.
  • 0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2025, filed 14 May 2025.